Novel Osmoprotective DOPC-DMPC Liposomes Loaded with Antihypertensive Drugs as Potential Strategy for Glaucoma Treatment

González-Cela-Casamayor, Miriam Ana; López-Cano, José Javier; Bravo‐Osuna, Irene; Andrés‐Guerrero, Vanessa; Vicario‐de‐la‐Torre, Marta; Guzmán-Navarro, Manuel; Benítez-del-Castillo, J.M.; Herrero–Vanrell, R.; Molina‐Martínez, Irene T.

doi:10.3390/pharmaceutics14071405

Cited by 8 publications

(4 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two liposome formulations loaded with either brimonidine or travoprost were created using synthetic phospholipids [ 78 ]. These liposomes were enriched with compounds possessing osmoprotective activity.…”

Section: Novel Technologiesmentioning

confidence: 99%

Technological Advances in a Therapy of Primary Open-Angle Glaucoma: Insights into Current Nanotechnologies

Zembala,

Forma,

Zembala

et al. 2023

JCM

View full text Add to dashboard Cite

Glaucoma is a leading cause of irreversible blindness and is characterized by increased intraocular pressure (IOP) and progressive optic nerve damage. The current therapeutic approaches for glaucoma management, such as eye drops and oral medications, face challenges including poor bioavailability, low patient compliance, and limited efficacy. In recent years, nanotechnology has emerged as a promising approach to overcome these limitations and revolutionize glaucoma treatment. In this narrative review, we present an overview of the novel nanotechnologies employed in the treatment of primary open-angle glaucoma. Various nanosystems, including liposomes, niosomes, nanoparticles, and other nanostructured carriers, have been developed to enhance the delivery and bioavailability of antiglaucoma drugs. They offer advantages such as a high drug loading capacity, sustained release, improved corneal permeability, and targeted drug delivery to the ocular tissues. The application of nanotechnologies in glaucoma treatment represents a transformative approach that addresses the limitations of conventional therapies. However, further research is needed to optimize the formulations, evaluate long-term safety, and implement these nanotechnologies into clinical practice. With continued advancements in nanotechnology, the future holds great potential for improving the management and outcomes of glaucoma, ultimately preserving vision and improving the lives of millions affected by this debilitating disease.

show abstract

Section: Novel Technologiesmentioning

confidence: 99%

Technological Advances in a Therapy of Primary Open-Angle Glaucoma: Insights into Current Nanotechnologies

Zembala,

Forma,

Zembala

et al. 2023

JCM

View full text Add to dashboard Cite

show abstract

“…In this work, we investigate the effects of adding 0.1-10 mol % of poly(ethylene glycol) modified (PEGylated) lipids on the assembly pathway of GUVs composed of the zwitterionic lipid DOPC (1,2-dioleoyl-sn-glycero-3-phosphocholine) through the PAPYRUS and gentle hydration methods. PEG2000-DSPE (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000]) has a long history of use in clinical lipid formulations because it improves the circulation lifetime by reducing opsonization of liposomes and lipid nanoparticles by serum proteins [17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32] . The lipid consists of an uncharged hydrophilic polymer of 45 repeating ethylene glycol monomer units with an average molecular weight of 2000 g/mol that is covalently attached to the headgroup of the phospholipid DSPE.…”

Section: Introductionmentioning

confidence: 99%

“…PEG2000-DSPE (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000]) has a long history of use in clinical lipid formulations because it improves the circulation lifetime by reducing opsonization of liposomes and lipid nanoparticles by serum proteins [17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32] . The lipid consists of an uncharged hydrophilic polymer of 45 repeating ethylene glycol monomer units with an average molecular weight of 2000 g/mol that is covalently attached to the headgroup of the phospholipid DSPE.…”

Section: Introductionmentioning

confidence: 99%

Ultrahigh yields of giant vesicles obtained through mesophase evolution and breakup

Cooper,

Subramaniam

2024

Preprint

View full text Add to dashboard Cite

Self-assembly odry amphiphilic lipid films on surfaces upon hydration is a crucial step in the formation of cell-like giant unilamellar vesicles (GUVs). GUVs are useful as model biophysical systems, as chassis for synthetic biology, and in biomedical applications. Here via combined quantitative measurements of the molar yield and distributions of sizes and high-resolution imaging of the evolution of lipid films on surfaces, we report the discovery of a previously unknown pathway for the assembly of GUVs which can lead to ultrahigh yields of > 50 %. This yield is about 60 % higher than any GUV yield reported to date. The “shear-induced fragmentation” pathway occurs in membranes containing 3 mol % of the poly(ethylene glycol) modified lipid PEG2000-DSPE (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000]), when a lipid-dense foam-like mesophase forms upon hydration. The membranes in the mesophase fragment and close to form GUVs upon application of fluid shear. Experiments with varying mol % of PEG2000-DSPE and with lipids with partial molecular similarity to PEG2000-DSPE show that ultrahigh yields are only achievable under conditions where the lipid-dense mesophase forms. The increased yield of GUVs compared to mixtures without PEG2000-DSPE was general to other flat supporting surfaces such as stainless steel sheets and to various lipid mixtures. Since FDA-approved liposomal and lipid nanoparticle formulations use PEG2000-DSPE, these results provide a useful route to obtaining ultrahigh yields of GUVs that are suitable for biomedical applications.

show abstract

“…The aim of the present research study was to encapsulate citicoline in a liposomal carrier with two different molar ratios, which is expected to improve the efficiency of drug delivery for possible ophthalmic applications. These vesicles are composed of 1,2-dioleoyl-sn-glycerol-3-phosphocholine (DOPC) and cholesterol (Chol) in two different molar ratios, (1:1) and (2:1), respectively [17,18]. The chemical characterization of the synthesized liposomes was evaluated in terms of particle size and surface charge, in vitro drug release, and physical stability.…”

Section: Introductionmentioning

confidence: 99%

Liposomal Encapsulation of Citicoline for Ocular Drug Delivery

Bonechi,

Mahdizadeh,

Talarico

et al. 2023

IJMS

View full text Add to dashboard Cite

Glaucoma represents a group of neurodegenerative diseases characterized by optic nerve damage and the slowly progressive death of retinal ganglion cells. Glaucoma is considered the second leading cause of irreversible blindness worldwide. Pharmaceutical treatment of glaucoma is critical because of the properties of the ocular barrier that limit the penetration of drugs, resulting in lower systemic bioavailability. This behavior causes the need of frequent drug administration, which leads to deposition of concentrated solutions on the eye, causing toxic effects and cellular damage to the eye. To overcome these drawbacks, novel drug-delivery systems, such as liposomes, can play an important role in improving the therapeutic efficacy of antiglaucomatous drugs. In this work, liposomes were synthesized to improve various aspects, such as ocular barrier penetration, bioavailability, sustained release of the drug, targeting of the tissue, and reduction in intraocular pressure. Citicoline (CDP-choline; cytidine 5′-diphosphocholine) is an important intermediate in the biosynthesis of cell membrane phospholipids, with neuroprotective and neuroenhancement properties, and it was used in the treatment on retinal function and neural conduction in the visual pathways of glaucoma patients. In this study, citicoline was loaded into the 1,2-dioleoyl-sn-glycerol-3-phosphocholine and cholesterol liposomal carrier to enhance its therapeutic effect. The citicoline encapsulation efficiency, drug release, and size analysis of the different liposome systems were investigated using dynamic light scattering, nuclear magnetic resonance, infrared spectroscopy, and ToF-SIMS experiments.

show abstract

Novel Osmoprotective DOPC-DMPC Liposomes Loaded with Antihypertensive Drugs as Potential Strategy for Glaucoma Treatment

Cited by 8 publications

References 67 publications

Technological Advances in a Therapy of Primary Open-Angle Glaucoma: Insights into Current Nanotechnologies

Technological Advances in a Therapy of Primary Open-Angle Glaucoma: Insights into Current Nanotechnologies

Ultrahigh yields of giant vesicles obtained through mesophase evolution and breakup

Liposomal Encapsulation of Citicoline for Ocular Drug Delivery

Contact Info

Product

Resources

About